Research on Sustainability of Inclusive Health Insurance in Rare Disease

China Health Insurance ›› 2022, Vol. 0 ›› Issue (6) : 108-112.

China Health Insurance ›› 2022, Vol. 0 ›› Issue (6) : 108-112. DOI: 10.19546/j.issn.1674-3830.2022.6.023
Commercial Insurance

Research on Sustainability of Inclusive Health Insurance in Rare Disease

Author information +
History +

Abstract

Objective: To summarize the guarantee mode of inclusive health insurance for rare diseases, and evaluate the impact of including rare diseases into the guarantee scope on the operation of inclusive health insurance, as to provide empirical evidence for further exploring the sustainable development path of inclusive health insurance for rare diseases. Methods: The guarantee mode of inclusive health insurance for rare diseases is summarized by selecting 62 products that does not limit the pre-existing conditions of rare diseases. Based on actuarial pricing technology, 5 high-value drugs for rare diseases with special clinical efficacy and urgent drug demand of patients and their corresponding universal benefit products with prominent insurance coverage are selected to conduct insurance cost analysis. Results: At present, the guarantee modes of inclusive health insurance for rare diseases mainly include insurance coverage in the medical insurance catalog, special drug coverage, hospitalization insurance coverage outside the medical insurance catalog and other coverage. Inclusive health insurance has sustainability in protecting rare diseases. Conclusion: Inclusive health insurance can make up for the protection gap of patients with rare diseases to a certain extent, but there is still a large room for improvement in the protection level of most products for rare diseases, and emphasis should be placed on optimizing the product protection responsibility of inclusive health insurance in the future. On the premise of fully considering local medical insurance policies and drug prices for rare diseases, inclusive health insurance can effectively balance operational risks by ensuring certain coverage rate and setting reasonable compensation standards, so as to achieve sustainability.

Key words

inclusive health insurance / rare diseases / sustainability / insurance actuarial pricing

Cite this article

Download Citations
Research on Sustainability of Inclusive Health Insurance in Rare Disease[J]. China Health Insurance. 2022, 0(6): 108-112 https://doi.org/10.19546/j.issn.1674-3830.2022.6.023

References

[1] 王雪,赵聪,许淑红,张绮,张林琦,王涛.我国罕见病用药可及性现状分析[J]. 中国临床药理学杂志,2021,37(08):1026-1032.
[2] 刘玉聪,董江萍.欧盟罕见病及孤儿药管理现状的研究[J]. 中国药学杂志,2012,47(05):395-398.
[3] 张晓星,周婷婷,潘杰.国内外罕见病用药保障模式的评述[J]. 中国卫生政策研究,2020,13(11):18-23.
[4] 阳义南,肖建华.罕见病医疗负担对支出型贫困的影响研究[J].中国卫生政策研究,2019,12(01):19-28.
[5] 陈永法,伍琳.我国罕见病界定标准初探[J].中国卫生政策研究,2014,7(10):16-20.
[6] 高嘉敏,马正.罕见病患者社会支持与生命质量的关系研究[J].中国卫生政策研究,2020,13(04):38-44.
[7] 孙宇航,王萍.国内外罕见病患者医疗保障现状探讨及启示[J]. 中国卫生质量管理,2019,26(03):141-145.
[8] 何山,高仕奇,何欣悦,刘鹏,金晔,李相言,朱以诚,陈丽萌,朱卫国,张抒扬.中国罕见病领域新进展(2020—2021)[J]. 协和医学杂志,2022,13(01):39-45.
[9] 中华人民共和国人力资源和社会保障部.国家基本医疗保险、工伤保险和生育保险药品目录(2021年)[EB/OL]. (2021-12-03)[2022-03-15]. http://www.mohrss.gov.cn/xxgk2020/fdzdgknr/shbx4216/gsbx/202112/t20211203429397.html
[10] 徐陆欣怡,王妮,尹适成,滕彩霞,崔丹.我国罕见病药品的可及性及采购使用现状研究[J].中国卫生政策研究,2022,15(02):60-64.
[11] 郭晋川,丁郑宁.普惠型商业补充医疗保险罕见病保障观察报告[R]. 2021.
[12] 南开大学卫生经济与医疗保障研究中心、北京病痛挑战公益基金会. 普惠型商业补充健康保险参与罕见病多层次保障[R]. 2022.
[13] 佛山市医疗保障局.关于2022年度佛山市商业补充医疗保险“平安佛医保”的参保公告 [EB/OL]. (2021-11-01)[2022-03-15]. http://www.foshan.gov.cn/gzjg/fsylbzj/zwdt/tzgg/content/post_5053856.html.
[14] 王子琪,闵连星,田兴军,萝莉,刘玉莲.我国罕见病医保政策的现状及优化路径[J]. 卫生经济研究,2021,38(11):22-25.
[15] 胡善联. 国内外罕见病的保障政策研究[J]. 卫生经济研究,2018(05):3-5.

Accesses

Citation

Detail

Sections
Recommended

/